ZA201602053B - Process for producing diazabicyclooctane derivative and intermediate thereof - Google Patents

Process for producing diazabicyclooctane derivative and intermediate thereof

Info

Publication number
ZA201602053B
ZA201602053B ZA2016/02053A ZA201602053A ZA201602053B ZA 201602053 B ZA201602053 B ZA 201602053B ZA 2016/02053 A ZA2016/02053 A ZA 2016/02053A ZA 201602053 A ZA201602053 A ZA 201602053A ZA 201602053 B ZA201602053 B ZA 201602053B
Authority
ZA
South Africa
Prior art keywords
producing
diazabicyclooctane derivative
diazabicyclooctane
derivative
producing diazabicyclooctane
Prior art date
Application number
ZA2016/02053A
Other languages
English (en)
Inventor
Abe Takao
Furuuchi Takeshi
Sakamaki Yoshiaki
Mitsuhashi Nakako
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of ZA201602053B publication Critical patent/ZA201602053B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ZA2016/02053A 2013-09-24 2016-03-29 Process for producing diazabicyclooctane derivative and intermediate thereof ZA201602053B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013197110 2013-09-24
PCT/JP2014/075203 WO2015046207A1 (ja) 2013-09-24 2014-09-24 ジアザビシクロオクタン誘導体の製造法とその中間体

Publications (1)

Publication Number Publication Date
ZA201602053B true ZA201602053B (en) 2019-06-26

Family

ID=52743343

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/02053A ZA201602053B (en) 2013-09-24 2016-03-29 Process for producing diazabicyclooctane derivative and intermediate thereof

Country Status (22)

Country Link
US (2) US10000491B2 (enExample)
EP (1) EP3050883B1 (enExample)
JP (1) JP6453222B2 (enExample)
KR (1) KR102239725B1 (enExample)
CN (2) CN105555787B (enExample)
AR (5) AR097744A1 (enExample)
AU (1) AU2014324302B2 (enExample)
BR (1) BR112016006246B8 (enExample)
CA (1) CA2924953C (enExample)
DK (1) DK3050883T3 (enExample)
ES (1) ES2793201T3 (enExample)
HK (1) HK1244487A1 (enExample)
HU (1) HUE049027T2 (enExample)
IL (1) IL244740B (enExample)
MX (2) MX367578B (enExample)
MY (2) MY193210A (enExample)
NZ (1) NZ718009A (enExample)
RU (1) RU2719480C2 (enExample)
SG (1) SG11201602256UA (enExample)
TW (1) TWI644908B (enExample)
WO (1) WO2015046207A1 (enExample)
ZA (1) ZA201602053B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201605368UA (en) 2012-05-30 2016-08-30 Meiji Seika Pharma Co Ltd NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
AU2014324302B2 (en) 2013-09-24 2018-02-15 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivative and intermediary body thereof
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
CA2969192C (en) 2014-12-05 2023-02-28 Meiji Seika Pharma Co., Ltd. A process for producing crystals of a diazabicylooctane derivative and a stable lyophilized composition thereof
CA2944306C (en) 2015-10-30 2023-11-14 The Toronto-Dominion Bank Validating encrypted data from a multi-layer token
US11216808B2 (en) 2015-11-04 2022-01-04 The Toronto-Dominion Bank Token-based system for excising data from databases
JP2020011901A (ja) * 2016-10-20 2020-01-23 協和キリン株式会社 ピロリジン化合物の製造方法
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
US10682413B2 (en) 2017-09-27 2020-06-16 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
US10584123B2 (en) 2017-09-27 2020-03-10 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
EP3687992A1 (en) 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivatives and production process thereof
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
EP3714046A1 (en) 2017-11-23 2020-09-30 H. Hoffnabb-La Roche Ag Proline hydroxylases as well as uses, methods and products involving the same
WO2020018462A1 (en) 2018-07-16 2020-01-23 Brown University A chromogenic beta-lactamase substrate
JP7523354B2 (ja) * 2018-09-21 2024-07-26 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
US12195755B2 (en) 2019-05-20 2025-01-14 Brown University Placental lipid bilayer for cell-free molecular interaction studies
US11751775B2 (en) 2019-08-30 2023-09-12 DePuy Synthes Products, Inc. Electrical device for monitoring, prevention, and treatment of implant infections
CN121021508A (zh) * 2025-10-29 2025-11-28 北京耀诚惠仁科技有限公司 β-内酰胺酶抑制剂中间体共晶或盐及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (enExample) 1970-10-21 1975-12-10
JPS538509A (en) 1976-07-13 1978-01-26 Toshiba Corp Impedance matching system for data transmission circuit
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (enExample) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
ES2127946T3 (es) * 1993-12-29 1999-05-01 Pfizer Antagonistas de neurocinina diazabiciclica.
US6111098A (en) 1994-05-02 2000-08-29 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2815420B1 (fr) 2000-10-16 2003-05-16 Cit Alcatel Compensation de la dispersion chromatique dans un systeme de transmission a fibre optique, et fibre de compensation
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
EP2231667B1 (en) 2008-01-18 2013-09-04 Merck Sharp & Dohme Corp. Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SG191320A1 (en) * 2010-12-22 2013-07-31 Meiji Seika Pharma Co Ltd Optically-active diazabicyclooctane derivative and method for manufacturing same
ES2560404T3 (es) * 2011-06-17 2016-02-18 Astrazeneca Ab Procesos para preparar compuestos heterocíclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma
RU2636147C1 (ru) 2011-08-27 2017-11-21 Вокхардт Лимитед Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
BR112013032974A2 (pt) 2011-08-30 2016-09-06 Wockhardt Ltd "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
MX349827B (es) 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
SG10201605368UA (en) 2012-05-30 2016-08-30 Meiji Seika Pharma Co Ltd NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
AU2014324302B2 (en) 2013-09-24 2018-02-15 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivative and intermediary body thereof
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法

Also Published As

Publication number Publication date
MX367578B (es) 2019-08-27
ES2793201T3 (es) 2020-11-13
AR131188A2 (es) 2025-02-26
AR131190A2 (es) 2025-02-26
JPWO2015046207A1 (ja) 2017-03-09
US10000491B2 (en) 2018-06-19
WO2015046207A1 (ja) 2015-04-02
TWI644908B (zh) 2018-12-21
MY193210A (en) 2022-09-26
EP3050883A4 (en) 2017-05-10
IL244740B (en) 2018-11-29
HK1244487A1 (zh) 2018-08-10
BR112016006246B8 (pt) 2021-10-05
RU2016115767A (ru) 2017-10-26
AU2014324302A1 (en) 2016-05-12
MX372585B (es) 2020-04-17
MY176278A (en) 2020-07-27
JP6453222B2 (ja) 2019-01-16
AR131189A2 (es) 2025-02-26
HK1219473A1 (zh) 2017-04-07
CN105555787A (zh) 2016-05-04
MX2016003867A (es) 2016-08-04
IL244740A0 (en) 2016-04-21
EP3050883A1 (en) 2016-08-03
CN105555787B (zh) 2017-08-08
BR112016006246A2 (enExample) 2017-08-22
US20160264573A1 (en) 2016-09-15
TW201546059A (zh) 2015-12-16
CA2924953C (en) 2021-12-07
CA2924953A1 (en) 2015-04-02
US20170283415A1 (en) 2017-10-05
CN107501264A (zh) 2017-12-22
HUE049027T2 (hu) 2020-08-28
AR097744A1 (es) 2016-04-13
KR102239725B1 (ko) 2021-04-12
SG11201602256UA (en) 2016-04-28
RU2719480C2 (ru) 2020-04-17
AR131186A2 (es) 2025-02-26
AU2014324302B2 (en) 2018-02-15
KR20160058851A (ko) 2016-05-25
NZ718009A (en) 2018-03-23
DK3050883T3 (da) 2020-05-25
RU2016115767A3 (enExample) 2018-06-29
US10000492B2 (en) 2018-06-19
BR112016006246B1 (pt) 2021-09-08
EP3050883B1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
ZA201602053B (en) Process for producing diazabicyclooctane derivative and intermediate thereof
EP3006415B8 (en) Method for producing nanocement and nanocement
SG11201508639WA (en) Method for producing methylmethacrylate
EP2987650A4 (en) TIRE AND METHOD FOR PRODUCING THE SAME
SG11201602587TA (en) Method for producing instant noodles and instant noodles
ZA201602054B (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
GB201312991D0 (en) Process
GB201315777D0 (en) Novel method
GB201307334D0 (en) Process
PL3043814T3 (pl) Antygen i sposób jego wytwarzania
HUE037007T2 (hu) Eljárás pirrol származék elõállítására és annak intermediere
PT3022283T (pt) Método e unidade para produção de microalgas
IL241287A0 (en) Processes for the preparation of subfervir
PL3069610T3 (pl) Ko-kryształ i sposób jego wytwarzania
SG11201506828WA (en) Process for producing butadiene
SG11201601958WA (en) Method for producing butadiene
HUP1300033A2 (en) Improved process for producing pharmaceutical agent and intermediate
EP2987470A4 (en) ENDOPROTHESIS AND METHOD FOR PRODUCING SAME
SG11201509952PA (en) Process for producing polyhydric alcohol
LT3008198T (lt) Katino sintezės būdas
HUP1300566A2 (en) Industrial process for producing steroid derivatives
GB201310151D0 (en) Novel method
GB201307327D0 (en) Process
GB201302441D0 (en) Process
IL242505B (en) A method for producing specific oximes and oximeters